InnoCare Pharma announced that it received IND approval for a Chinese clinical trial to study the effects of new SHP2 allosteric inhibitor, ICP-189.

Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.

NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.

Myeloid Therapeutics, a clinical-stage cancer treatment company, has given the first dose of MT-302 to a patient in a Phase 1 trial for advanced or metastatic epithelial tumors.

Replicate Bioscience has administered the first dosage of its RBI-4000 vaccine to a participant.

Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.

Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.

BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.

Takeda has shared positive initial results from its Phase 2b trial, on TAK-279, a selective, orally administered TYK2 inhibitor, which is assessed for its efficacy in treating active psoriatic arthritis.

LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.

Phase 3 CheckMate-227 Trial's findings confirm enduring, extended survival with Opdivo combined with Yervoy with Metastatic Non-Small Cell Lung Cancer.

Blue Earth Therapeutics released preclinical study results on the potency, lipophilicity, absorption, and efficacy of 225Ac-rhPSMA-10.1 in prostate cancer models, compared to 177Lu-rhPSMA-10.1. Both showed strong binding, excellent absorption, and similar lipophilicity.